I disagree, TC and gd4, I am usually a very hard critic

New Post Public Reply Private Reply Replies (2) Message Board
Zolis_onkel gd4nthing #15221
350
I disagree, TC and gd4,

I am usually a very hard critic for the PRs that GNBT has released in the past several months. But here I absolutely like the tone of their writing, and I really do see the meat on the bones. What I do read out of it as well is caution, because they do not want to sound too optimistic, just to make sure that nobody can in the end sue them for making promises that they are finally not able to keep. Especially with the federal government involved, they have made their experiences and learned that such predictions need to be made very carefully.
HOWEVER, what I DO like about this PR very much is, that at least I can read a lot of confidence out of it, that they will be able to walk the route that they describe in this PR. They very clearly describe the steps that they are planning to take on the route towards having a vaccine ready, tested, approved and produced in large quantaties within the given time frame of 6 months (or maybe a little longer, if things are not running as smoothly, as they are hoping for).

I read confidence out of the fact that they are now already preparing themselves and starting collaborations with organizations that could produce the vaccine in large quantities, once approved. If they would not be sure that they will be able to provide something that can be approved soon, why would they already plan the next three steps ahead? And these steps are very clearly layed out and concrete. I really do like that.
I read confidence out of the statement that "From our knowledge, the U.S. government has nothing like the Generex COVID 19 Complete Vaccine technology in their pandemic preparedness portfolio."

With that said, we are best in class, and a clear plan/strategy on how to get to a working - and in large quantities available - vaccine, in place, I think the federal funding made available to GNBT is just a question of finalizing the paperwork and a matter of a couple of more days, until all these hopes, wants and believes are going to materialize in front of us.

After this PR from yesterday, I am more confident than ever, that GNBT will be able to do it and after they have sold millions of vaccine doses, will have no further funding issues and can move on with all the other amunition that they have in their arsenal.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 9

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading

Top 5 Most Recently Viewed Articles

Nvidia's Skyrocketing Stock: Comparing With Bitcoin Returns

Updated Category News Views 155

Nvidia's Remarkable Growth in the Stock Market Nvidia Corp., famously led by CEO Jensen Huang, continues to impress investors with its exceptional financial performance, especially in the realm of artificial intelligence (AI). Recently, the company announced a staggering third-quarter revenue of $35.1 billion, coupled with earnings per share of 81 cents, surpassing...

Continue Reading
Celebrating Katharine Morgan: A Pioneer Award for Leadership

Updated Category News Views 181

Katharine Morgan's retirement from ASTM International was a watershed moment back in 2023. The organization wasn't just losing a president; it was saying goodbye to a true pioneer in the field of standardization. She’d kicked off her journey way back in 1984 and climbed the ranks like a seasoned pro, ultimately becoming the first female president of ASTM. Now that’s...

Continue Reading
Arcadis Transitions to New CFO: Willem Baars Steps Up

Updated Category News Views 524

Arcadis Announces CFO Transition: A New Chapter Begins Arcadis, recognized as a global leader in sustainable design, engineering, and consultancy solutions, is undergoing a significant transition in its executive leadership. Virginie Duperat-Vergne will step down as Chief Financial Officer (CFO) and a member of the Executive Board, effective from 31 May 2025. This...

Continue Reading
The BLVD Group Launches Major Affordable Housing Project

Updated Category News Views 289

The BLVD Group Launches Major Affordable Housing Project The BLVD Group, renowned for its commitment to creating affordable housing, is thrilled to announce an innovative redevelopment initiative. They are set to enhance Concord Royal Gardens, a significant 300-unit affordable housing community, with a total investment of $97 million. This endeavor, which involves...

Continue Reading
Altimmune Unveils Pemvidutide Clinical Data at Diabetes Meeting

Updated Category News Views 63

Altimmune Showcases Pemvidutide at European Diabetes Conference Altimmune, Inc. (Nasdaq: ALT), a leading clinical-stage biopharmaceutical company, has announced an exciting development regarding its innovative treatment, pemvidutide. The company is preparing to present significant findings from its Phase 2 clinical study at the esteemed 60th Annual Meeting of the European...

Continue Reading